Cited by 940Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Egen, Jackson G., Kuhns, Michael S., Allison, James P.·2002·Nature Immunology

Open this paper in CoChat — free account

Abstract

The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.

Integrity signals

Registry

Crossref · 10.1038/ni0702-611

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
The B7–CD28 superfamily
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

Show all 93 references

Sorted by citations

Items 601–700 of 940

Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies
Leaf, R. K., Cho, H. J., & Avigan, D. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0283-0 · Cited by 18
Enhanced Antitumor Responses Elicited by Combinatorial Protein Transfer of Chemotactic and Costimulatory Molecules
Liu, S., Breiter, D. R., Zheng, G., & Chen, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.3301 · Cited by 16
T-cell signaling and costimulatory molecules in B-chronic lymphocytic leukemia (B-CLL): an increased abnormal expression by advancing stage
Rossmann, E. D., Jeddi‐Tehrani, M., Österborg, A., & Mellstedt, H. (2003) · Leukemia · doi:10.1038/sj.leu.2403100 · Cited by 16
Peptide Vaccines Against Cancer
Berzofsky, J. A., Oh, S., & Terabe, M. (2005) · Cancer treatment and research · doi:10.1007/0-387-27545-2_5 · Cited by 16
Circulating levels and clinical significance of soluble CD86 in myeloma patients
Hock, B. D., Drayson, M. T., Patton, W. N., Taylor, K., Kerr, L., & McKenzie, J. L. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.05983.x · Cited by 16
CTLA-4 Engagement and Regulatory CD4+CD25+ T Cells Independently Control CD8+-Mediated Responses under Costimulation Blockade
Coenen, J. J. A., Koenen, H. J. P. M., van Rijssen, E., Boon, L., Joosten, I., & Hilbrands, L. B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5240 · Cited by 16
Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future
Morel, V. J., Rössler, J. K., & Bernasconi, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22059 · Cited by 18
Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation
Pilat, N., Schwarz, C. C., & Wekerle, T. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e328355fc94 · Cited by 15
Immunomodulating antibodies and drugs for the treatment of hematological malignancies
Houot, R., Kohrt, H. E. K., Goldstein, M. J., & Levy, R. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9274-3 · Cited by 16
The rationale for prophylactic cancer vaccines and need for a paradigm shift
Sobol, R. E. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700950 · Cited by 15
Detection and frequency estimation of rare variants in pools of genomic DNA from large populations using mutational spectrometry
Li-Sucholeiki, X., Tomita‐Mitchell, A., Arnold, K., Glassner, B. J., Thompson, T. G., Murthy, J. V., Berk, L., Lange, C. S., Leong-Morgenthaler, P.-M., MacDougall, D., et al. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.11.004 · Cited by 15
General Principles of Tumor Immunotherapy
Kaufman, H. L., & Wolchok, J. D. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8 · Cited by 15
Monoclonal antibody therapy of ovarian cancer
Nicodemus, C. F., & Berek, J. S. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.1.87 · Cited by 15
Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics
Smith, F. D., Pierce, R. H., Thisted, T., & van der Horst, E. H. (2023) · Antibodies · doi:10.3390/antib12030055 · Cited by 14
Human CD8+ T-regulatory cells with low-avidity T-cell receptor specific for minor histocompatibility antigens
Burlingham, W. J., & Goulmy, E. (2008) · Human Immunology · doi:10.1016/j.humimm.2008.08.289 · Cited by 14
Biological Therapies for Cancer
Price, K., & Rao, G. K. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00013-7 · Cited by 14
Breast cancer and immunology: biomarker and therapeutic developments
Santa-Maria, C. A., Park, S. J., Jain, S., & Gradishar, W. J. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1086270 · Cited by 14
Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade
Mauzo, S. H., Tetzlaff, M. T., Nelson, K. C., Amaria, R. N., Patel, S. P., Aung, P. P., Nagarajan, P., Torres-Cabala, C. A., Diab, A. K., Prieto, V. G., et al. (2017) · International Journal of Dermatology · doi:10.1111/ijd.13833 · Cited by 14
A case of immune checkpoint inhibitor‐associated gastroenteritis detected by ultrasonography
Omotehara, S., Nishida, M., Yamanashi, K., Sakurai, K., Katsurada, T., Komatsu, Y., Shimizu, A., Shibuya, H., Shinagawa, N., Sugita, J., et al. (2021) · Journal of Clinical Ultrasound · doi:10.1002/jcu.22975 · Cited by 14
Impact of the Immunological Synapse on T Cell Signaling
Dustin, M. L. (2006) · Springer eBooks · doi:10.1007/400_019 · Cited by 14
Differential requirements for CD80/86–CD28 costimulation in primary and memory CD4 T cell responses to vaccinia virus
Fuse, S., Tsai, C., Rommereim, L. M., Zhang, W., & Usherwood, E. J. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.09.008 · Cited by 15
Genetic variations in cytotoxic T-lymphocyte antigen-4 and susceptibility to cervical cancer
Xiong, Y., He, L., & Jing, F. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.10.018 · Cited by 14
Intracellular concentrations of Ca2+ modulate the strength of signal and alter the outcomes of cytotoxic T‐lymphocyte antigen‐4 (CD152)–CD80/CD86 interactions in CD4+ T lymphocytes
Ahmed, A., Mukherjee, S., & Nandi, D. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02902.x · Cited by 14
Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options
Chakravarty, D., Huang, L. T., Kahn, M., & Tewari, A. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.07.010 · Cited by 13
Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances
Nigam, S., Bishop, J. O., Hayat, H., Quadri, T., Hayat, H., & Wang, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030644 · Cited by 13
A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review
Sharafi, F., Hasani, S. A., Alesaeidi, ‬., Kahrizi, M. S., Adili, A., Ghoreishizadeh, S., Shomali, N., Tamjidifar, R., Aslaminabad, R., & Akbari, M. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02682-z · Cited by 13
Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer
Muaibati, M., Abasi, A., Zhang, T., Dai, Y., Li, R., Huang, F., Li, K., Tong, Q., Huang, X., & Zhuang, L. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.3 · Cited by 13
Effect of cytotoxic T-lymphocyte-associated protein 4 on CD4+CD25+ regulatory T cells in murine Schistosomiasis japonica
Tang, C., Lei, J., Guan, F., Li, Y., Liu, R., Grevelding, C. G., Jiang, M.-S., & Dong, H. (2013) · Experimental Parasitology · doi:10.1016/j.exppara.2013.11.001 · Cited by 13
Pivotal Advance: CTLA-4+ T cells exhibit normal antiviral functions during acute viral infection
Raué, H.-P., & Slifka, M. K. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0806535 · Cited by 13
Role of Vaccine Therapy in Cancer: Biology and Practice
Schlom, J., Gulley, J. L., & Arlen, P. M. (2007) · Current Oncology · doi:10.3747/co.2007.158 · Cited by 13
Influence of cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms in periodontitis
Houshmand, B., Rafiei, A., & Hajilooi, M. (2012) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2012.03.002 · Cited by 13
Controversies in the Management of Advanced Melanoma
Jarkowski, A., Norris, L. B., & Trinh, V. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014544165 · Cited by 12
Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies
Maulhardt, H. A., Verco, S. J., Baltezor, M. J., Marin, A. M., & diZerega, G. S. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01226-2 · Cited by 12
Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model
Ghosh, S., He, X., Huang, W., & Lovell, J. F. (2022) · APL Bioengineering · doi:10.1063/5.0099811 · Cited by 12
The Current and Emerging Role of Immunotherapy in Prostate Cancer
Madan, R. A., & Gulley, J. L. (2010) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2010.n.002 · Cited by 12
Distribution of CTLA-4 Polymorphisms in Allergic Asthma
Jasek, M., Łuszczek, W., Obojski, A., Winiarska, B., Hałubek, K., Nowak, I., Mańczak, M., Wiśniewski, A., Pawlik, A., Jonkisz, A., et al. (2006) · International Archives of Allergy and Immunology · doi:10.1159/000095292 · Cited by 12
Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model
Li, N., Qin, H., Li, X., Zhou, C., Wang, D., Ma, W., Chen, L., Zhang, Y., Wang, S., & Zhang, S. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.07.019 · Cited by 12
Structure Based Screening for Inhibitory Therapeutics of CTLA-4 Unveiled New Insights About Biology of ACTH
Ramezani, A., Zakeri, A., Mard‐Soltani, M., Mohammadian, A., Hashemi, Z. S., Mohammadpour, H., Jahangiri, A., Khalili, S., & Rasaee, M. J. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09891-7 · Cited by 12
Monoclonal Antibodies in Therapy of Solid Tumors
Heimann, D. M., & Weiner, L. M. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.001 · Cited by 12
Costimulation-based immunotherapy for head and neck cancer
Strome, S. E., & Chen, L. (2004) · Current Treatment Options in Oncology · doi:10.1007/s11864-004-0003-9 · Cited by 12
Using antibodies in tumour immunotherapy
Schultes, B. C., & Nicodemus, C. F. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.8.1265 · Cited by 12
Role of regulatory T cells in cancer
Mir, M. A., & Mir, A. Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18696-7.00001-4 · Cited by 11
Artificial intelligence in immunotherapy PET/SPECT imaging
McGale, J., Chen, D. L., Trebeschi, S., Farwell, M. D., Wu, A. M., Cutler, C. S., Schwartz, L. H., & Dercle, L. (2024) · European Radiology · doi:10.1007/s00330-024-10637-3 · Cited by 11
Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?
Ntemou, E., Delgouffe, E., & Goossens, E. (2024) · Cancers · doi:10.3390/cancers16061176 · Cited by 11
Plasma checkpoint protein levels and galectin-9 in juvenile systemic lupus erythematosus
Yüksel, K., Sağ, E., Demir, S., Özdel, S., Akça, Ü. K., Atalay, E., Cüceoğlu, M. K., Topaloğlu, R., Bilginer, Y., & Özen, S. (2021) · Lupus · doi:10.1177/09612033211002275 · Cited by 11
The Future of Cancer Treatment: Will It Include Immunotherapy?
Bluestone, J. A., & Small, E. J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.009 · Cited by 11
Neutrophils releasing IL-17A into NETs are essential to plasma cell differentiation in inflamed tissue dependent on IL-1R
Grund, L. Z., Novaski, I., Quesniaux, V. F. J., Ryffel, B., Lopes‐Ferreira, M., & Lima, C. (2016) · Autoimmunity · doi:10.1080/08916934.2016.1261834 · Cited by 11
Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions
Maulhardt, H. A., Marin, A. M., Hesseltine, H., & diZerega, G. S. (2021) · Medical Oncology · doi:10.1007/s12032-021-01555-1 · Cited by 11
CTLA4 A49G Polymorphism Shows Significant Association With Glioma Risk in a Chinese Population
Wu, Q., Zhan, X., Dou, T., Chen, H., Fan, W., Zhou, K., Zhang, H., Zheng, H., Cai, Y., Zhao, Y., et al. (2010) · Biochemical Genetics · doi:10.1007/s10528-010-9398-0 · Cited by 11
Accumulation of CD25+ CD4+ T-cells in the draining lymph node during the elicitation phase of DNCB-induced contact hypersensitivity in lambs
Gunnes, G., Jörundsson, E., Tverdal, A., Landsverk, T., & Press, C. M. (2004) · Research in Veterinary Science · doi:10.1016/j.rvsc.2004.03.008 · Cited by 11
Construction and Characterization of a CTLA-4-Targeted scFv–Melittin Fusion Protein as a Potential Immunosuppressive Agent for Organ Transplant
Jin, H., Li, C., Ding, L., Cai, M., Li, Z., Wang, S., Hong, X., & Shi, B. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9605-9 · Cited by 11
Strategies to reverse melanoma-induced T-cell dysfunction
Fourcade, J. J., & Zarour, H. M. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.010 · Cited by 11
Viewpoint: Therapeutic Implications of CTLA-4 Compartmentalization
Baroja, M. L., & Madrenas, J. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00182.x · Cited by 11
Vaccine strategies to treat lymphoproliferative disorders
Radford, K. J., Vari, F., & Hart, D. N. J. (2005) · Pathology · doi:10.1080/00313020500376462 · Cited by 11
Immune Checkpoints in Solid Organ Transplantation
Bello, A. D., & Treiner, E. (2023) · Biology · doi:10.3390/biology12101358 · Cited by 10
3‐Methylcholanthrene‐induced transforming growth factor‐β‐producing carcinomas, but not sarcomas, are refractory to regulatory T cell‐depletion therapy
Chamoto, K., Wakita, D., Ohkuri, T., Uchinami, Y., Matsushima, K., Kitamura, H., & Nishimura, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01469.x · Cited by 10
The genetic and epigenetic basis of distinct melanoma types
Oba, J., & Woodman, S. E. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15957 · Cited by 10
Pan-cancer analysis reveals the relationship between RCSD1 immune infiltration and clinical prognosis in human tumors
Qiao, H., Yin, H. X., Feng, Y., & Tang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1008778 · Cited by 10
Pulmonary Toxicities of Immunotherapy
Altan, M., Zhong, L., Shannon, V. R., & Sheshadri, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_14 · Cited by 10
Biochemical analysis of CTLA-4 immunoreactive material from human blood
Tector, M., Khatri, B. O., Kozinski, K. M., Dennert, K., & Oaks, M. K. (2009) · BMC Immunology · doi:10.1186/1471-2172-10-51 · Cited by 10
The novel bispecific diabody αCD40/αCD28 strengthens leukaemic dendritic cell‐induced T‐cell reactivity
Houtenbos, I., Santegoets, S. J. A. M., Westers, T. M., Waisfisz, Q., Kipriyanov, S. M., Denkers, F., Scheper, R. J., de Gruijl, T. D., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.06990.x · Cited by 10
Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2
Mukherjee, S., Ahmed, A., Malu, S., & Nandi, D. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0505260 · Cited by 10
Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma
Lendvai, N. K., Cohen, A. D., & Cho, H. J. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.5 · Cited by 9
Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review
Ocaña‐Guzmán, R., Osorio-Pérez, D., & Chávez‐Galán, L. (2023) · Pharmaceuticals · doi:10.3390/ph16081119 · Cited by 9
Radiothérapie et immunomodulation : mise au point sur les données expérimentales
Deutsch, É., Lévy, A., & Chargari, C. (2015) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2015.05.018 · Cited by 9
Mathematical Modelling of the Inhibitory Role of Regulatory T Cells in Tumor Immune Response
Yang, Z., Yang, C., Dong, Y., & Takeuchi, Y. (2020) · Complexity · doi:10.1155/2020/4834165 · Cited by 9
Zaburzenia odpowiedzi immunologicznej w raku płuca—Nowy cel terapii
Domagala-Kulawik, J. J., & Osińska, I. (2014) · Advances in respiratory medicine · doi:10.5603/piap.2014.0034 · Cited by 9
Molecularly targeted therapy and immunotherapy for hormone receptor‑positive/human epidermal growth factor receptor 2‑negative advanced breast cancer (Review)
Song, Y., He, L., Wang, Y., Wu, Q., & Huang, W. (2020) · Oncology Reports · doi:10.3892/or.2020.7589 · Cited by 9
The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis
Xu, Y., Hezam, K., Ali, M. G., Wang, Y., & Zhang, J. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1924195 · Cited by 9
Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia
Wölfl, M., Qayed, M. D., Benítez‐Carabante, M. I., Sýkora, T., Bonig, H. B., Lawitschka, Á., & de Heredia, C. D. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.784377 · Cited by 9
Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis
Huo, G., Liu, W., Zhang, S., & Chen, P. (2023) · Immunotherapy · doi:10.2217/imt-2022-0140 · Cited by 9
T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
Campoli, M. R., & Ferrone, S. (2004) · Expert Review of Vaccines · doi:10.1586/14760584.3.2.171 · Cited by 9
Investigating expression pattern of eight immune‐related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy
Tavakolpour, S., Mahmoudi, H., Karami, F., Behjati, S. E., Balighi, K., Abbasi, M., Farid, A. S., Masoudi, J., Balali, M., Daneshpazhooh, M., et al. (2020) · Dermatologic Therapy · doi:10.1111/dth.14380 · Cited by 9
Immune Checkpoints: Therapeutic Targets for Pituitary Tumors
Nie, D., Xue, Y., Fang, Q., Cheng, J., Li, B., Wang, D., Li, C., Gui, S., Zhang, Y., & Zhao, P. (2021) · Disease Markers · doi:10.1155/2021/5300381 · Cited by 9
Immunotherapy of melanoma
Hersey, P. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01269.x · Cited by 9
Knocking the SOCS1 off dendritic cells
Gilboa, E. (2004) · Nature Biotechnology · doi:10.1038/nbt1204-1521 · Cited by 9
Vaccines to treat cancer‐an old approach whose time has arrived
Hellström, K. E., & Hellström, I. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21468 · Cited by 9
Proteomics in cancer vaccine development
Shoshan, S. H., & Admon, A. (2005) · Expert Review of Proteomics · doi:10.1586/14789450.2.2.229 · Cited by 9
Activation of thymic T cells by MHC alloantigen requires syngeneic, activated CD4+ T cells and B cells as APC
Strutt, T. M., Uzonna, J. E., McKinstry, K. K., & Bretscher, P. A. (2006) · International Immunology · doi:10.1093/intimm/dxl009 · Cited by 9
Immune Escape
Whiteside, T. L., Campoli, M. R., & Ferrone, S. (2005) · Springer eBooks · doi:10.1007/1-4020-3623-x_3 · Cited by 9
Integrated profile of tumor stage and mutational burden predicts disparate clinical responses to immune checkpoint inhibitors: A risk-benefit study
Zheng, M. (2024) · Seminars in Oncology · doi:10.1053/j.seminoncol.2024.08.003 · Cited by 8
BRAF and MEK Gene Rearrangements in Melanoma: Implications for Targeted Therapy
Madureira, P., & de Mello, R. A. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0081-0 · Cited by 8
The role and relationship between programmed death ligand 1 and cytotoxic T lymphocyte-associated antigen-4 immunohistochemical expression in colorectal carcinoma patients; an impact on outcome
Mohamed, A. S. E. D., El-Rebey, H. S., Aboelnasr, L. S., & Abdou, A. G. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1323 · Cited by 8
An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy
Sibilio, P., Belardinilli, F., Licursi, V., Paci, P., & Giannini, G. (2022) · Biology Direct · doi:10.1186/s13062-022-00324-y · Cited by 8
Endolysosomal transient receptor potential mucolipins and two-pore channels: implications for cancer immunity
Ouologuem, L., & Bartel, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1389194 · Cited by 8
Lentiviral delivery of CTLA‑4 shRNA improves the expansion of cytokine‑induced killer cells and enhances cytotoxic activity in vitro
Tao, R., Cheng, X., Wu, H., Wang, F., Ye, Z., & Wu, G. (2017) · Oncology Letters · doi:10.3892/ol.2017.7376 · Cited by 8
Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis
Derambure, C., Dzangué-Tchoupou, G., D’Agostino, M. A., Lequerré, T., & Vittecoq, O. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237143 · Cited by 8
PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective
Wáng, Q., Zhang, X., Wei, W., & Cao, M. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00353 · Cited by 8
Current and planned multicenter trials for patients with primary or metastatic melanoma
Sondak, V. K., Han, D., Deneve, J. L., & Kudchadkar, R. R. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21867 · Cited by 8
Comprehensive Evaluation of the Cytotoxic T-Lymphocyte Antigen-4 Gene Polymorphisms in Risk of Bone Sarcoma
Liu, S., Geng, P., Cai, X., & Wang, J. (2014) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2014.0023 · Cited by 8
Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer
Zhao, X., May, A., Lou, E., & Subramanian, S. (2018) · Translational research · doi:10.1016/j.trsl.2018.02.001 · Cited by 9
Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy
Abdkarimi, S., Soofiyani, S. R., Elham, G., Abdolahi, H. M., Safarzadeh, E., & Baradaran, B. (2020) · European Journal of Cancer Care · doi:10.1111/ecc.13268 · Cited by 9
T Cell Costimulatory Molecules in Anti‐Viral Immunity: Potential Role in Immunotherapeutic Vaccines
Watts, T. H., Bertram, E. M., Bukczynski, J., & Wen, T. (2003) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2003/214034 · Cited by 8
Genetic modification of T cells for immunotherapy
Berger, C., Berger, M., Feng, J., & Riddell, S. R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.8.1167 · Cited by 8
Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity
Foster, J. C., Freidlin, B., Korn, E. L., & Smith, M. A. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000871 · Cited by 7
Mitochondrial pathogenic mutations are population-specific
Breen, M. S., & Kondrashov, F. A. (2010) · Biology Direct · doi:10.1186/1745-6150-5-68 · Cited by 7
Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET
Hartimath, S., Draghiciu, O., Daemen, T., Nijman, H. W., van Waarde, A., Dierckx, R., & de Vries, E. F. J. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01447-x · Cited by 7
Analysis of regulatory T cells and CTLA-4 expression in pregnant women according to seropositivity toToxoplasma gondii
Rezende-Oliveira, K., Gómez‐Hernández, C., da Silva, M. V., Helmo, F. R., & Rodrigues, V. (2020) · Parasitology · doi:10.1017/s0031182020000475 · Cited by 7
Monoclonal Antibody Therapy for Hematologic Malignancies
Foon, K. A., Boyiadzis, M. M., & Jacobs, S. A. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_15 · Cited by 7
Antiviral T cell responses
Posnett, D. N., Engelhorn, M. E., & Houghton, A. N. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050928 · Cited by 7

Authors: Egen, J. G., Kuhns, M. S., & Allison, J. P.
Affiliations: Howard Hughes Medical Institute (US)
Corresponding author: Allison, James P.
ORCID: Egen, Jackson G.
Kuhns, Michael S.
Allison, James P.
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2002-07
Volume: 3
Issue: 7
Pages: 611-618
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni0702-611
OpenAlex: W2140460887
Cited by: 940
References: 93
Citations by year: 2026: 10 · 2025: 15 · 2024: 30 · 2023: 34 · 2022: 45 · 2021: 50 · 2020: 43 · 2019: 33 · 2018: 27 · 2017: 36 · 2016: 28 · 2015: 32 · 2014: 31 · 2013: 38 · 2012: 25
FWCI: 5.88
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (CA40041, R01CA057986, CA57986)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, costimulatory receptors, CD28, T cell activation, T cell receptor signaling, T cell regulation, cancer immunotherapy, CTLA-4 blockade, immune checkpoint blockade
MeSH terms: Abatacept, Animals, Antigens, Differentiation, Cell Division, Colonic Neoplasms, Disease Models, Animal, Fibrosarcoma, Gene Expression Regulation, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Antigens, CD, Immunoconjugates, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks